Stephen Westaby
Oprichter bij Calon Cardio-Technology Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Martin Evans | M | 83 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | 15 jaar |
Ajan Reginald | M | 52 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | 15 jaar |
Sabena Sultan | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Bernard J. Taylor | M | 67 |
University of Oxford
| - |
Marc Clement | M | - |
Calon Cardio-Technology Ltd.
Calon Cardio-Technology Ltd. Medical SpecialtiesHealth Technology Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom. | 17 jaar |
Ronald John Petersen | M | - |
Calon Cardio-Technology Ltd.
Calon Cardio-Technology Ltd. Medical SpecialtiesHealth Technology Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom. | - |
David Preston | M | 57 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Ian Gardiner | M | - |
University of Oxford
| - |
Peter W. Hinchliffe | M | - |
Calon Cardio-Technology Ltd.
Calon Cardio-Technology Ltd. Medical SpecialtiesHealth Technology Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom. | - |
Peter Grindrod | M | - |
University of Oxford
| - |
Robin Hanson | M | - |
University of Oxford
| - |
Judith Patricia Armitage | M | - |
University of Oxford
| - |
George Radda | M | - |
University of Oxford
| - |
Peter Hunter | M | - |
University of Oxford
| - |
Anil Razdan | M | 75 |
University of Oxford
| - |
Jayne Almond | F | 67 |
University of Oxford
| - |
André Finn | M | - |
University of Oxford
| - |
Ngaire Woods | F | 62 |
University of Oxford
| 14 jaar |
Peter Friend | M | - |
University of Oxford
| - |
Ashok Kumar Bhattacharya | M | 78 |
University of Oxford
| - |
Jeff Orenstein | M | - |
University of Oxford
| - |
Katherine Mary Barker | F | 66 |
University of Oxford
| - |
Marcus du Sautoy | M | - |
University of Oxford
| - |
Robert Fry | M | - |
University of Oxford
| - |
Malcolm McCulloch | M | - |
University of Oxford
| - |
Indrajit Wickramasinghe | M | - |
University of Oxford
| - |
Stephen Pulman | M | - |
University of Oxford
| - |
Matthew David Robson | M | 55 |
University of Oxford
| - |
Jan Tadeusz Czernuszka | M | - |
University of Oxford
| - |
Robert MacLaren | M | 57 |
University of Oxford
| - |
KENNEDY LIZBETH | F | - |
Calon Cardio-Technology Ltd.
Calon Cardio-Technology Ltd. Medical SpecialtiesHealth Technology Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom. | 6 jaar |
Sheila Barrett | F | - |
University of Oxford
| - |
Hearth Henrietta | F | - |
University of Oxford
| 3 jaar |
Chas Bountra | M | 64 |
University of Oxford
| - |
Nigel James Scott | M | 73 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Duncan Mark Powell Ribbons | M | 46 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Lee Phillip Chapman | M | 48 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Li Jin | M | 54 |
University of Oxford
| - |
J. Doyne Farmer | M | 72 |
University of Oxford
| - |
Stefan Karl Neubauer | M | - |
University of Oxford
| - |
Zhan Feng Cui | M | 62 |
University of Oxford
| - |
Harry Hoelzer | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 jaar |
David Kerr | M | - |
University of Oxford
| - |
Maria Damanaki | F | 72 |
University of Oxford
| - |
Robyn Norton | F | - |
University of Oxford
| - |
Stephen MacMahon | M | - |
University of Oxford
| - |
Leonard Charles William Seymour | M | 66 |
University of Oxford
| - |
Cheryl Musch | F | - |
University of Oxford
| - |
Mike Chalfen | M | - |
University of Oxford
| - |
Darrin Disley | M | 57 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Ronald Daniel | M | - |
University of Oxford
| - |
Robert J. Champion de Crespigny | M | - |
University of Oxford
| - |
John Bell | M | 71 |
University of Oxford
| 35 jaar |
Stephen George Franklin | M | 77 |
University of Oxford
| - |
Anthony Charles Hotson | M | 70 |
University of Oxford
| - |
Stephen Davies | M | 74 |
University of Oxford
| 28 jaar |
Bill Spitz | M | 72 |
University of Oxford
| - |
Patrick Pichette | M | 61 |
University of Oxford
| - |
Tiong Lu Koh | M | 68 |
University of Oxford
| - |
Herman Waldmann | M | - |
University of Oxford
| - |
Robert Charles Wigley | M | 63 |
University of Oxford
| - |
Soo Min Yeoh | F | 68 |
University of Oxford
| - |
Lionel Tarassenko | M | 67 |
University of Oxford
| 27 jaar |
Lai Kuen Louey | M | 64 |
University of Oxford
| 13 jaar |
Barden N. Gale | M | 73 |
University of Oxford
| - |
Alan J. Kingsman | M | 73 |
University of Oxford
| - |
Victor Blank | M | - |
University of Oxford
| - |
William Castell | M | 76 |
University of Oxford
| - |
Crispin Davis | M | 75 |
University of Oxford
| - |
Raj Bhikhu Parekh | M | 63 |
University of Oxford
| - |
William R. Miller | M | 95 |
University of Oxford
| - |
David M. Upton | M | 64 |
University of Oxford
| - |
André S. Hoffmann | M | 66 |
University of Oxford
| - |
Adrian V. S. Hill | M | - |
University of Oxford
| - |
William Scott-Jackson | M | - |
University of Oxford
| - |
Patrick Thomas | M | 67 |
University of Oxford
| - |
Len Blavatnik | M | 66 |
University of Oxford
| - |
Alan J. Edwards | M | - |
University of Oxford
| - |
Leonard W. Seymour | M | - |
University of Oxford
| - |
Geoffrey Hale | M | - |
University of Oxford
| - |
Peter Ratcliffe | M | 69 |
University of Oxford
| - |
E. Kristine Klavers | F | - |
University of Oxford
| - |
John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 jaar |
Wendy Becker | F | 58 |
University of Oxford
| - |
Alan Moore | M | - |
University of Oxford
| - |
John Martin O'Loan | M | - |
University of Oxford
| - |
Horace Deets | M | - |
University of Oxford
| - |
David Kirn | M | 62 |
University of Oxford
| - |
Marc Feldmann | M | 79 |
University of Oxford
| 13 jaar |
Geert Linnebank | M | 68 |
University of Oxford
| - |
Nigel Shadbolt | M | 68 |
University of Oxford
| - |
Michael Sydney Perry | M | - |
University of Oxford
| - |
Li Jin | M | 53 |
University of Oxford
| 12 jaar |
Benjamine Reid | M | - |
University of Oxford
| - |
Alex Hawker | M | - |
University of Oxford
| - |
Julie Baddeley | F | 73 |
University of Oxford
| - |
Simon Boddie | M | 64 |
University of Oxford
| 3 jaar |
Jane Green | M | - |
University of Oxford
| - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Simon Cartmell | M | 64 |
Calon Cardio-Technology Ltd.
Calon Cardio-Technology Ltd. Medical SpecialtiesHealth Technology Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Stephen Westaby
- Persoonlijk netwerk